Daily Endocrinology Research Analysis
Analyzed 11 papers and selected 3 impactful papers.
Summary
Analyzed 11 papers and selected 3 impactful articles.
Selected Articles
1. Non-linear association of coagulation factor XI with mortality.
In 3,170 angiography patients followed for 14.5 years, FXI activity showed a U-shaped association with mortality overall, with minimum risk near 116%. The relationship differed by CAD status (linear risk increase in CAD) and was modified by NT-proBNP, underscoring the need for personalized antithrombotic strategies and tailored FXI inhibitor trials.
Impact: Reveals context-dependent, non-linear mortality risk linked to FXI activity, directly informing the development and patient selection for FXI inhibitors.
Clinical Implications: Consider FXI activity as a risk marker where available; extremes or elevated levels—especially in CAD—may warrant closer monitoring. FXI inhibitor trials should stratify by CAD and NT-proBNP and avoid one-size-fits-all targets.
Key Findings
- Overall U-shaped association between FXI activity and mortality with nadir at 115.6% activity (p=0.027).
- In CAD patients, higher FXI activity correlated linearly with increased mortality (p for interaction <0.0001).
- In non-CAD patients, the U-shaped mortality association persisted.
- NT-proBNP significantly modified FXI–mortality associations, especially in CAD.
Methodological Strengths
- Large, well-characterized cohort (N=3,170) with long median follow-up (14.5 years).
- Advanced modeling (restricted cubic splines) with multivariable adjustment and interaction analyses.
Limitations
- Observational design limits causal inference and residual confounding cannot be excluded.
- Generalizability may be limited to patients undergoing coronary angiography.
Future Directions: Validate FXI–mortality thresholds externally; prospectively test CAD- and NT-proBNP-stratified strategies in FXI inhibitor trials to refine therapeutic windows.
2. The effect of resveratrol supplementation on anthropometric indices, adiponectin and leptin levels in individuals with overweight and obesity: a graded, systematic review and meta-analysis of randomized controlled trials.
Across 23 RCTs (n=1005), resveratrol supplementation did not significantly alter weight, BMI, fat mass, adiponectin, or leptin, but modestly reduced waist circumference (~1.9 cm). Subgroup signals suggest potential benefits at lower doses, longer durations, and in women, warranting targeted trials rather than routine supplementation.
Impact: Provides high-level evidence clarifying that resveratrol is unlikely to produce clinically meaningful weight or adipokine changes, preventing ineffective supplementation while identifying specific contexts for future testing.
Clinical Implications: Do not recommend resveratrol for weight loss or adipokine modulation in overweight/obesity. A small reduction in waist circumference may be possible; if used, consider lower doses (<1000 mg/day) and ≥12-week courses, particularly in women, pending confirmatory RCTs.
Key Findings
- No significant effects on body weight, BMI, fat mass, body fat percentage, fat-free mass, WHR, adiponectin, or leptin.
- Significant reduction in waist circumference (WMD −1.93 cm; 95% CI −3.10 to −0.76; p=0.001).
- Subgroup analyses: weight and BMI reductions at doses <1000 mg/day, ≥12-week interventions, and in females.
- FFM increased in participants <50 years; leptin increased in both sexes.
Methodological Strengths
- PROSPERO-registered protocol (CRD42024497932) with comprehensive database search (Scopus, WoS, PubMed).
- Inclusion limited to randomized controlled trials with quantitative synthesis across 23 RCTs (n=1005).
Limitations
- Heterogeneity in dosing, duration, and participant characteristics; subgroup findings may be hypothesis-generating.
- Potential publication bias and outcome measurement variability were not detailed in the abstract.
Future Directions: Conduct adequately powered RCTs with standardized dosing (<1000 mg/day), ≥12-week duration, and sex-stratified analyses focused on central adiposity outcomes.
3. Peri-renal and sinus fat accumulation and diabetic kidney disease in type 2 diabetes: A Japanese cohort study.
Over 15 years in 190 Japanese adults with T2D, CT-quantified renal adiposity—especially renal sinus fat—improved prediction of incident DKD beyond BMI and abdominal adiposity. These data position local renal fat as a potentially actionable biomarker for early DKD risk stratification.
Impact: Introduces imaging-based local renal fat as an independent predictor of DKD, refining risk models beyond conventional adiposity metrics.
Clinical Implications: Renal sinus fat quantification may strengthen DKD risk stratification in T2D and guide early preventive strategies, though CT-based measurement requires consideration of radiation and access.
Key Findings
- In a 15-year cohort, PRFVI and especially RSFVI predicted DKD independently of conventional risk factors.
- CT-derived local renal fat measures outperformed general (BMI) and abdominal adiposity indices for DKD prediction.
- Participants were stratified into tertiles across five adiposity indices to compare predictive performance.
Methodological Strengths
- Prospective long-term cohort with imaging-based adiposity quantification.
- Multimetric comparison (BMI, VFA, SFA, PRFVI, RSFVI) enabling incremental value assessment.
Limitations
- Single-country cohort with modest sample size (n=190), which may limit generalizability.
- CT-based fat measurement involves radiation exposure and may not be widely available.
Future Directions: Validate RSFVI/PRFVI in larger, multi-ethnic cohorts; explore MRI-based quantification and interventional strategies to reduce renal sinus fat and DKD risk.